X4 Pharmaceuticals Inc Total Liabilities
X4 Pharmaceuticals Inc total liabilities. Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has total liabilities worth $97.61 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of X4 Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of X4 Pharmaceuticals Inc (2015–2025)
Total liabilities of X4 Pharmaceuticals Inc from 2015 to 2025. This chart illustrates how X4 Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
X4 Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blend Labs Inc
NYSE:BLND
|
USA | $217.17 Million |
|
Bold Eagle Acquisition Corp. Class A Ordinary Shares
NASDAQ:BEAG
|
USA | $9.73 Million |
|
Aluflexpack AG
SW:AFP
|
Switzerland | CHF290.87 Million |
|
JAKKS Pacific Inc
NASDAQ:JAKK
|
USA | $200.62 Million |
|
MC Group Public Company Limited
BK:MC
|
Thailand | ฿1.90 Billion |
|
Bangyan Technology Co. Ltd. A
SHG:688132
|
China | CN¥277.68 Million |
|
K&F Growth Acquisition Corp. II Unit
NASDAQ:KFIIU
|
USA | $10.15 Million |
|
TianJin JinRong TianYu Precision Machinery Inc.
SHE:300988
|
China | CN¥1.01 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down X4 Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see X4 Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
X4 Pharmaceuticals Inc Total Liabilities Ratios Explained
X4 Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how X4 Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual total liabilities of X4 Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $104.17 Million | -16.19% |
| 2024-12-31 | $124.30 Million | +29.26% |
| 2023-12-31 | $96.16 Million | +17.94% |
| 2022-12-31 | $81.53 Million | +54.53% |
| 2021-12-31 | $52.76 Million | +5.38% |
| 2020-12-31 | $50.07 Million | +59.07% |
| 2019-12-31 | $31.48 Million | +118.54% |
| 2018-12-31 | $14.40 Million | -36.12% |
| 2017-12-31 | $22.55 Million | -7.32% |
| 2016-12-31 | $24.33 Million | +75.22% |
| 2015-12-31 | $13.88 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more